News & Blog
Published in the Oncologist, the research found that the rate of opioid dispensing and the amount of opioids dispensed for patients experiencing cancer with bone metastasis decreased.
The Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH) is thrilled to have Dr. Victoria Behar-Zusman joining as a member of the Center Advisory Board. Dr. Behar-Zusman is a principal investigator of the Center for Latino Health Research Opportunities (CLaRO) and leads the Investigator Development Core at the […]
After direct-acting antiviral agents to treat hepatitis C were introduced, most of those who prescribed treatment was gastroenterology specialists but there was an increasing proportion of non-specialists. Treatment completion rates were similar between specialists and non-specialists.
In our study, we found that implementation of comprehensive prescription drug monitoring programs (PDMP) mandates were associated with reductions in opioids dispensed within three days of emergency department encounters of patients with sickle cell disease or cancer with bone metastasis.
After reviewing the articles, the authors found studies that provide new evidence supporting the cost-effectiveness of buprenorphine compared with no medication.
The authors found that discontinuation, defined by a gap of 14-or-more days in medication coverage, was common across all four medications for opioid use disorder.